CAC
HALO icon

Cowen and Company’s Halozyme HALO Stock Holding History

Cowen and Company’s Portfolio HALO Stock Details HALO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-54,034
Closed -$2M – 692
2023
Q4 		$2M Buy
+54,034
New +$2.04M 0.13% 117
2021
Q3 		– Sell
-10,480
Closed -$438K – 644
2021
Q2 		$476K Buy
10,480
+2,967
+39% +$131K 0.02% 185
2021
Q1 		$313K Buy
+7,513
New +$343K 0.02% 230

Other funds holding HALO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SCM
Snyder Capital Management San Francisco, California $5.16B AUM 26.72% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
TD Asset Management
TD Asset Management Toronto, Ontario, Canada $123B AUM 34.51% 1-Year Est. Return

Cowen and Company's HALO Position: Q1 2024 in Review

Cowen and Company sold out of Halozyme (HALO) in Q1 2024, closing a stake of 54,034 shares — an estimated $2M sold.

Cowen and Company first reported a position in HALO in Q1 2021 and held it in 3 quarters. The position peaked at $2M in Q4 2023. 414 funds tracked by Wall St. Rank hold HALO as of Q1 2024.

  • Cowen and Company reported no remaining Halozyme position as of Q1 2024 after selling out during the quarter.
  • Cowen and Company sold 54,034 Halozyme shares in Q1 2024, an estimated $2M.
  • Cowen and Company first reported a position in Halozyme in Q1 2021 and held it in 3 quarters.
  • Cowen and Company's Halozyme position peaked at $2M in Q4 2023.
  • 414 funds tracked by Wall St. Rank held Halozyme as of Q1 2024.

Based on Cowen and Company's 13F filing for Q1 2024, filed 3 May 2024.